NL-OMON41065已完成不适用
A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects with Hepatitis C Infection - MK8408-003
Merck Sharp & Dohme (MSD)0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male or Female (of non-child bearing potential) subjects with verified HCV infection with
- •GT1a, GT2b or GT3 between the ages of 18 and 65 years (inclusive)
- •2. have a Body Mass Index (BMI) >=18 to <=37 kg/m2
- •3. Be judged to be in good health, except for HCV infection
排除标准
- •1. Subject is mentally or legally institutionalized / incapacitated, has significant emotional problems at the time of pretrial (screening) visit or expected during the conduct of the trial or has a history of clinically significant psychiatric disorder of the last 5 years.
- •2. Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological
- •(including stroke and chronic seizures) abnormalities or diseases.
- •3.Subject has a history of cancer.
研究者
相似试验
进行中（未招募）
1 期
The CO-ANNEXIN study; assessing the efficacy and safety of ANXV (recombinant Annexin A5) in moderate tosevere COVID-19.moderate to severe COVID-19 pneumoniaEUCTR2021-002200-12-NLMUMC AZm12
尚未招募
2 期
A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed moderate to severe COVID-19; The CO-ANNEXIN Study.COVID-19 pneumoniaSARS-COV-2 infection100038161004743810037454NL-OMON51226Medisch Universitair Ziekenhuis Maastricht12
终止
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseNCT02220738AbbVie19
已完成
1 期
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)Hepatitis CNCT00998985Merck Sharp & Dohme LLC91
已完成
不适用
A Multiple Dose Study of the Safety and Pharmacology of LY2165766SchizophreniaNL-OMON33078Chorus LRL (Division of Eli Lilly)20